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Abstract
Background: Protein kinase A type I (PKAI) and PKAII are expressed in most of the eukaryotic cells examined. PKA
is a major receptor for cAMP and specificity is achieved partly through tissue-dependent expression and subcellular
localization of subunits with different biochemical properties. In addition posttranslational modifications help fine
tune PKA activity, distribution and interaction in the cell. In spite of this the functional significance of two forms of
PKA in one cell has not been fully determined. Here we have tested the ability of PKAI and PKAII formed by
expression of the regulatory (R) subunits RIa or RIIa in conjunction with Ca1 or Cb2 to activate a co-transfected
luciferace reporter gene, controlled by the cyclic AMP responsive element-binding protein (CREB) in vivo.
Results: We show that PKAI when expressed at equal levels as PKAII was significantly (p < 0.01) more efficient in
inducing Cre-luciferace activity at saturating concentrations of cAMP. This result was obtained regardless of
catalytic subunit identity.
Conclusion: We suggest that differential effects of PKAI and PKAII in inducing Cre-luciferace activity depend on R
and not C subunit identity.
Background
Cyclic 3’, 5’-adenosine monophosphate (cAMP) is a key
intracellular signaling molecule, which main function is
to activate the cAMP-dependent protein kinases (PKA)
[1,2]. PKA is a heterotetrameric holoenzyme composed
of two regulatory (R) and two catalytic (C) subunits,
which is enzymatically inactive in the absence of cAMP.
When two molecules of cAMP bind to each of the R
subunits [3], the C subunits are released and activated
to phosphorylate serine and threonine residues on speci-
fic intracellular target proteins [4,5]. Several PKA sub-
strates have been identified of which the synthetic
peptide Kemptide [6] and the naturally occurring sub-
strate cAMP responsive element binding protein (CREB)
are of the best characterized [7,8]. In primates, four
genes encoding the R subunit and four genes encoding
the C subunit, have been identified and designated RIa,
RIb, RIIa, RIIb and Ca, Cb, Cg and X-chromosome
encoded protein kinase X (PrKX) [9].
Whereas no splice variants for RIb and RIIb have been
described, RIa is transcribed from at least two different
promoters. The first exons of the RIa gene, exon 1a and
1b, give rise to alternatively spliced but identical pro-
teins RIa1a and RIa1b [10]. RIa 1a and 1b mRNAs
have been identified in most tissues and are differen-
tially regulated by cAMP [11-13]. In the case of RII, it
has been shown that RIIa in the human testis but no
other tissues examined, is encoded with an alternative
amino-terminal region [14]. No functional consequences
of alternative splicing of RI and RII have been reported.
Several splice variants are transcribed from the Ca
and the Cb genes (PRKCA and PRKCB) and include
Ca1, CaS, Cb1, Cb2, Cb3 and Cb4, in addition to an
unknown number of abc forms of the Cb3 and Cb4 var-
iants [15-20]. The major differences between the various
C subunits are introduced through alternative use of
exon 1 in the PRKCB and PRKCA genes, respectively
[16,21,22]. In the case of Ca1 exon 1-1 encodes an
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N-terminal stretch of 14 amino acids that have three
sites that undergo co- and posttranslational modifica-
tions. At the very N-terminus a Gly is located that
undergoes myristoylation in vivo [23]. C-terminal to the
Gly an Asn is located that is partly deamidated in vivo
leading to Ca1-Asp2 and Ca1-iso(b)Asp2 [24]. The
third modification is PKA-autophosphorylation at Ser10
[25-27]. In the case of Cb2, exon 1-2 encodes an
N-terminal stretch of 62 amino acids that does not har-
bor sites for any of the modifications identified in Ca1.
Instead, the Cb2 N-terminus contains a stretch of
hydrophobic amino acids that form an amphiphatic
a-helix displayed as a hydrophobic surface [20]. Ca1
and Cb1 are more than 90% identical at the amino acid
level and are ubiquitously expressed. CaS has only been
identified in sperm cells [28], Cb2 is predominantly
expressed in lymphoid cells [29,30], and Cb3 and Cb4
and their abc variants are mainly expressed in neuronal
tissues [15,16].
It is assumed that any known C subunit may associate
with RI and RII to form PKAI and PKAII, respectively
[9]. This has raised the question of the biological signifi-
cance of PKAI and II holoenzymes containing various C
isoforms within the same cell. Whereas no reports have
been published on the functional consequences of
holoenzymes formed with various C subunits, it has
been demonstrated that several cell types expressing
RIa are highly proliferative and may also be associated
with malignancy [31-34]. Using a genetic approach it
has also been demonstrated that constitutive ablation of
RIa but not RIb is prenatal lethal whereas ablation of
the RII variants results in more discrete defects, affect-
ing differentiation of adipose tissue and neural functions
[35-37]. The levels of RI and RII as well as tissue- and
subcellular expression varies. They also show differential
affinities for A-kinase anchoring proteins (AKAP).
Furthermore, when determining the structure of the
PKA holoenzymes it was found that RI and RII contact
the substrate binding site of the C subunit either as a
true PKA substrate (RII) or as a pseudosubstrate (RI)
due to autophosphorylation of RII but not RI at Ser95
[38,39]. Despite these differences an explanation for bio-
logical differences at the cellular level between RI and
RII are not fully appreciated [40,41]. However, it should
be noted that RII autophosphorylation modulates
AKAP-RII interaction in cardiac cells, leading to altered
down-stream substrate phosphorylation and Ca2+
dynamics [42].
To investigate biological differences between RI and
RII and to demonstrate if such differences are depen-
dent on C subunit identity we formed PKAI and PKAII
by co-transfecting 293T cells with either RIa or RIIa
together with Ca1 and Cb2, respectively. This demon-
strated that PKAI was superior to PKAII in activating a
cAMP responsive element regardless of whether the
holoenzyme contained Ca1 or Cb2. Our results contri-
bute to understand the functional significance of two
PKA holoenzymes but not various C subunits expressed
in the same cell.
Results
To test for differential roles of PKAI and PKAII
expressed in one cell we tested if markedly different C
subunits released from RI and RII are equally effective in
regulating in vivo substrate phosphorylation. We chose
the cell line 293T as a model system since they express
RIa and RIIa associated with Ca1 (Figure 1A, left panel),
and not RIb and RIIb (Figure 1A, right panel). In these
cells PKAI and PKAII are distinctly located to the cytosol
and Golgi-centrosomal area, respectively as demonstrated
by immunostaining using anti-RIa (red) or anti-RIIa
(green) (Figure 1B). Co-immunostaining with anti-C
demonstrated that Ca1 localization corresponded to
R subunit localization. We also observed a weak
nuclear staining of the C subunit in the absence of cAMP
(Figure 1C), whereas in the presence of the cAMP analo-
gue, 8-CPT-cAMP (340 µM) an increase in nuclear stain-
ing was observed (Figure 1C). We concluded that the
293T cells represented a suitable model system to study
isoform differences between PKAI and PKAII formed
with different C subunits.
To obtain 293T cells dominated by either PKAI or
PKAII expression, we formed holoenzymes by transient
transfection of plasmids over-expressing either RIa or
RIIa (pDeRIa or pExRIIa) in combination with either
Ca1 or Cb2 (pDeCa1 or pDeCb2). For some experi-
ments the cells were also transfected with a vector
expressing Luciferace controlled by a cAMP responsive
element. C subunit activity was tested in vitro using
Kemptide as a substrate [43,44]; and in vivo using the
Cre-Luciferase reporter system [45]. This revealed a
dose-dependent increase in PKA-specific catalytic activity
against Kemptide for both pDeCa1 and pDeCb2 with a
maximum at 5600 ng DNA (Figure 2A). The luciferase
response was bell shaped and reached a maximum for
pDeCa1 and pDeCb2 at 1400 and 2800 ng DNA, respec-
tively (Figure 2B). Next, we titrated the plasmids expres-
sing RI and RII by transfecting 0-1280 ng of the plasmids
pDeRIa and pExRIIa, respectively (Figure 2C, D).
Twenty four hours after transfection cells were lysed
and R subunit levels were measured by immunoblotting
and [3H]-cAMP-binding. This revealed an increase in a
49 kDa immunoreactive band as well as increased [3H]-
cAMP-binding that coincided with the amount of plas-
mid transfected (pDeRIa, Figure 2C). The same was the
case when transfecting pExRIIa (Figure 2D). Together
this demonstrated a dose-dependent expression of both
RIa and RIIa.
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Based on these transfections and earlier experiments
(results not shown), we next formed PKA holoenzymes
by R and C co-transfections. We aimed at transfecting R
plasmids to levels where C activity in the absence of
cAMP were at basal levels, implying levels of R able to
associate with all C subunits. 293T cells were co-
transfected with a fixed amount of either pDeCa1
(300 ng) or pDeCb2 (1400 ng) together with increasing
amounts of pDeRIa (0-1280 ng, Figure 3A, B) and pEx-
RIIa (0-1280 ng, Figure 3C, D), respectively. Cell
extracts were adjusted to 1 mg total protein/mL and
total C subunit activity measured in the presence and
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Figure 1 PKAI (RIaCa1) and PKAII (RIIaCa1) are expressed in 293T cells. (A) Cell extracts of 293T cells (40 μg protein/lane) were analyzed
by immunoblotting using a pan-anti-C antibody (upper left panel) and anti-RIa and anti-RIIa (lower left panels). The levels and identities of 293T
cell C and R subunit expression were compared to human peripheral blood lymphocytes (hPBL) revealing expression of Ca1, RIa and RIIa. No
detectable levels of RIb and RIIb were identified when compared to extracts of human temporal cortex (hTempCortex, right panels).
(B) Immunofluorescence analysis of PKA RI and RII in 293T cells. RIa (Anti-RI, red) is expressed diffusely in the cytosol and RIIa (Anti-RII, green) is
expressed in the Golgi-centrosomal area of 293T cells. (C) Immunofluorescence analysis of PKA C subunits in 293T treated without (-) or with (+)
340 μM 8-CPT-cAMP.
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absence of 7.14 μM cAMP. This demonstrated that Ca1-
specific kinase activity was inhibited down to basal levels
in the absence of cAMP at 640 ng pDeRIa (Figure 3A),
which was equal to 28 ± 1.4 pmol RIa/mg total protein
(Table 1). In the case of Cb2-specific activity it was down
to basal levels in the absence of cAMP at 80 ng pDeRIa
(Figure 3B) which was equal to 11.8 ± 2.7 pmol RIa/mg
total protein (Table 1). For RIIa, 320 ng pExRIIa was
required for optimal Ca1 inhibition (Figure 3C), which
was equal to 16.2 ± 0.5 pmol RIIa/mg total protein
0 1000 2000 3000 4000 5000 6000
0
50000
100000
150000 A
CD1
CE2
D NA(ng)
PK
A 
sp
ec
ific
 e
nz
ym
e 
ac
tiv
ity
0 1000 2000 3000 4000 5000 6000
0
5000
10000
15000 B
CD1
CE2
D NA  (ng )
Re
lat
ive
 lu
cif
er
as
e 
ac
tiv
ity
0
2500
5000
7500
10000
12500
M
V
10
40
80
160
320
640
1280
R II D D N A  (ng)
R IID
D
52
M
o
le
c
u
la
r 
m
a
s
s
 (
k
D
a
)
[0
2500
5000
7500
10000
R ID
C
M
V
10
40
80
160
320
640
1280
R I D D NA  (ng )
49
M
o
le
c
u
la
r 
m
a
s
s
 (
k
D
a
)
[3 H
]- 
cA
M
P
 b
in
di
ng
 a
ct
ivi
ty
 
3 H
]- 
cA
M
P
 b
in
di
ng
 a
cti
vit
y 
Figure 2 Activity of PKA R and C subunits expressed in 293T cells. (A and B) 293T cells were left untransfected, transfected with empty vector
(vector) or with increasing amounts (0 - 5600 ng) of either pDeCa1 (Ca1,—) or pDeCb2 (Cb2,————). After 24 hours cells were harvested,
homogenized and all cell extracts adjusted to 1 mg total protein/mL. PKA activity was determined as catalytic activity against Kemptide in the
presence of 7.14 μM cAMP (A) and Luciferase activity at 560 nm (B). Data points represent enzyme activity and relative luciferase activity,
respectively, +/- SD, n = 3. (C and D) 293T cells were left untransfected, transfected with empty vector (vector) or with increasing amounts (10 -
1280 ng) of either pDeRIa or pExRIIa. Levels of R subunit expression were monitored as [3H]-cAMP-binding and R subunit immunoreactivity against
RIa (C, clone 4D7, 1: 300 dilution) or anti-RIIa (D, 1 : 400 dilution) after SDS-PAGE separation of 25 μg total protein per lane in 12.5 % gels. R subunit
activities are given as cpm +/- SD (n = 3). The apparent molecular weight of protein recognized is indicated by arrows and protein identity RIa (49
kDa) and RIIa (52 kDa), given by arrows to the left. One immunoblot out of three independent experiments is shown.
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(Table 1). Finally, 80 ng pExRIIa was required to inhibit
Cb2 activity to basal levels (Figure 3D) which was equal
to 9.6 ± 2 pmol RIIa/mg total protein. In order to com-
pare in vitro and in vivo PKA activity, protein extracts
were analyzed against Kemptide phosphorylation and
luciferace activity after transfection with Cage-
Cre-Luciferase (700 ng) together with either 300 ng
pDeCa1 or 1400 ng pDeCb2 and increasing amounts of
pDeRIa and pExRIIa (160-1280 ng DNA, Figure 4A-D).
In these experiments psv-b-Galactosidase (1000 ng) was
used for normalization (see Methods). This showed that
luciferase activity induced by Ca1 and Cb2 was comple-
tely inhibited by both RIa and RIIa at doses above or
equal to 640 ng plasmid DNA.
The experiments in Figures 3 and 4 depict that Cb2
activity is fully inhibited at lower amounts of R than Ca1
is. This may imply that Ca1 is enzymatically more active
than Cb2 or simply that Cb2 is more unstable than Ca1
in the absence of R. A previous report shows that the C
subunit in its free active form is more rapidly degraded
than C complexed with the R subunit dimer [46]. To test
if Ca1 and Cb2 display differential stability, identical
amounts of Ca1 and Cb2 plasmids were transfected alone
or with 1280 ng of pDeRIa. This confirmed (Figure 5 bars
2 and 3) that in the absence of RIa total Cb2 activity is
significantly (* p< 0.05) lower compared to Ca1. This was
not the case when RIa was co-transfected with the two C
subunits. In this case both Ca1 and Cb2 activities were
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Figure 3 Expressed RIa and RIIa inhibit expressed Ca1 and Cb2 catalytic activity in a dose-dependent manner. 293T cells were co-
transfected with increasing amounts (0-1280 ng) of either pDeRIa (A and B) or pExRIIa (C and D) with a fixed amount of pDeCa1 (300 ng, A
and C) or pDeCb2 (1400 ng, B and D). Cells were harvested after 24 hours, cell extracts adjusted to 1 mg total protein/mL and assayed for PKA-
specific phosphotransferase activity in the presence (+ cAMP) and absence (- cAMP) of 7.14 μM cAMP. Data points represent pmol ATP
transferred/min/mg protein) +/- SD (n = 2-6).
Table 1 Concentrations of RI and RII required for
maximal inhibition of transfected C subunit
Subunits Ca1 (300 ng DNA) Cb2 (1400 ng DNA)
RIa 28 ± 1.4* 11.8 ± 2.7
RIIa 16.2 ± 0.5 9.6 ± 2
*Concentration of R subunit (pmol/mg protein) required for 100% inhibition of
Ca1 and Cb2 activity.
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increased, however, to comparable levels after stimulation
with cAMP (bars 5 and 7, ns). This demonstrated that RIa
has a stabilizing effect on both C subunits. However the
effect was more pronounced for Cb2 than Ca1 indicating
that Cb2 is more unstable than Ca1 in the absence of R.
The results from Figures 3 and 4 demonstrated that
we had obtained cell systems dominated by either PKAI
or PKAII. Hence, the effects of PKAI and PKAII on in
vitro (Kemptide) and in vivo (CREB) phosphorylation
could be tested. For these experiments we used amounts
of RIa and RIIa required for complete inhibition of
Ca1 and Cb2 respectively.
After 24 hours cell extracts were diluted to 1 mg total
protein/mL and analyzed for cAMP dose-dependent
induction of PKA kinase activity against Kemptide
(Figure 6A, C). Both RIa and RIIa were able to inhibit
Ca1 and Cb2 kinase activity completely in the absence
of cAMP. When increasing the concentrations of cAMP
from 5 to 5000 nM, kinase activity was peaking, in the
case of Ca1 at 100 nM cAMP when co-expressed with
RIa and between 500 and 5000 nM when co-expressed
with RIIa. In the case of Cb2, maximum activity was
achieved at concentrations between 500 and 5000 nM
cAMP when co-expressed with both RIa and RIIa. We
further analyzed C subunit activity in vivo by measuring
luciferace activity. Activity was measured after stimula-
tion of the transfected cells with increasing concentra-
tions of 8-CPT-cAMP (0 - 320 μM) for 1 hour prior to
harvesting. We observed that activity associated with
Ca1 and Cb2 released from both RIa and RIIa
increased in a dose-dependent manner, reaching maxi-
mum between 160 and 320 μM 8-CPT-cAMP (Figure
6B, D). However, a more than two fold higher activity
was observed against CREB when Ca1 and Cb2 were
released from RIa than from RIIa. Together these
results indicated that the ability of C to phosphorylate
nuclear substrates in vivo at saturating concentrations of
cAMP when associated with PKAII was lower than
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Figure 4 Expressed RIa and RIIa inhibit Ca1- and Cb2-dependent CREB phosphorylation in a dose-dependent manner. 293T cells were
co-transfected with increasing amounts (0-1280 ng) of either pDeRIa (A and B) or pExRIIa (C and D) and a fixed amount of pDeCa1 (300 ng, A
and C) or pDeCb2 (1400 ng, B and D). Cells were harvested after 24 hours and cell extracts adjusted to 1 mg total protein/mL and assayed at
560 nm for PKA-specific phosphorylation of CREB measured as CRE-activity. Data points represent relative luciferase activity +/- SD (n = 2-6).
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when associated with PKAI. This was apparent despite
that total C subunit activity in vitro was comparable and
protein concentrations were equal (Figure 6A to 6D).
Since these results were seen regardless of C subunit
isoform we suspected that the differences observed were
associated with R subunit identity. To quantify the dif-
ferent efficacy of PKAI and PKAII to phosphorylate
CREB in vivo, we therefore co-transfected pDeRIa (640
ng) and pExRIIa (320 ng) with Ca1 (300 ng pDeCa1)
and monitored [3H]-cAMP binding. This showed equal
activities (Figure 7A) and hence comparable levels
(Table 2) revealed as 22 ± 1.5 and 23 ± 1.5 pmol per
mg total protein of RIa and RIIa, respectively. We next
determined C subunit activity in vitro after transfecting
cells as described in Figure 7A, and in the absence (0
nM) and presence of two concentrations of cAMP (5
and 5000 nM). This revealed basal activity in the
absence, and low level activity in the presence of 5 nM
cAMP whereas 5000 nM cAMP resulted in comparable
high levels of total C subunit activity released from both
PKAI and PKAII (Figure 7B). The C activities were
equal to 25 ± 1.4 and 24.2 ± 2.9 pmol Ca1 per mg total
protein for PKAI and PKAII, respectively (Table 2). This
concluded that PKAI and PKAII were expressed at com-
parable levels under the present conditions. The latter
was substantiated by a calculated R to C ratio close to 1
for both RIa versus Ca1 (ratio 0.88) and RIIa versus
Ca1 (ratio 0.96, Table 2).
In lymphoid cells, it has been demonstrated that R subu-
nits are more stable in the holoenzyme form compared to
the free R subunit [47]. To test if the presence of Ca1
alone and in conjunction with cAMP would influence R
subunit levels we transfected 293T cells with either
pDeRIa (640 ng) or pExRIIa (320 ng) alone or in conjunc-
tion with pDeCa1 (300 ng). Transfected cells were treated
without (0) or with incremental doses (1-320 μM) of
8-CPT-cAMP for four hours before harvesting. Equal
amounts of cell extracts (50 μg total protein per lane) were
analyzed for proteins immunoreactive to anti-RIa and
anti-RIIa, respectively. Figure 7C shows that 8-CPT-cAMP
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Figure 5 Ca1 and Cb2 proteins are stabilized by RIa. 293T cells were untransfected (M) or transfected with fixed amounts of either pDeCa1
(300 ng) or pDeCb2 (1400 ng) in conjunction with 1280 ng (bars 4 to 7) or without (bars 1-3) pDeRIa for 24 h. Cell extracts were adjusted to 1
mg total protein/mL and assayed for PKA-specific phosphotransferase activity in the absence (- cAMP) and presence (+ cAMP) of 320 nM cAMP.
Data points represent pmol ATP transferred/min/mg protein) +/- SD (n = 3). The relative activities of Cb2 and Ca1 in the absence of RIa were
significantly different (*p < 0.02, bars 2 and 3). When Ca1 and Cb2 were co-transfected with RIa the relative activities were indistinguishable
(bars 5 and 7, ns).
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stimulation appeared not to influence R subunit levels and
thus the cAMP sensitivity of the system.
Based on our observations (Figure 6B and 6D), we
transfected cells as described in Figure 7B with equal
amounts of PKAI and PKAII and monitored luciferace
activity after stimulation with two concentrations of 8-
CPT-cAMP (1 and 320 μM) for 1 hour before harvest-
ing. As depicted in Figure 7D 320 μM 8-CPT-cAMP
induced more than a 13-fold increase in luciferace activ-
ity when associated with RIa compared to untreated
cells. When associated with RIIa the induction was 3-
fold. This difference was reflected in a relative induction
of luciferace activity which was nearly twice as high for
PKAI compared to PKAII (1.94 fold, p < 0.01).
Discussion
Despite that PKAI and PKAII are located to different
areas when expressed in the same cell, it is believed that
when dissociated by cAMP, the C subunits are all
released to phosphorylate relevant substrates both in the
cytosol and nucleus [48]. We formed PKAI and PKAII
holoenzymes by co-transfecting 293T cells with RIa or
RIIa together with either Ca1 or Cb2.
We found that C subunits, irrespective of isoform,
appeared more efficient in inducing Cre-luciferase when
released from PKAI than PKAII.
To monitor total PKA activity in vitro and in vivo we
applied cAMP and the cAMP analogue 8-CPT-cAMP.
In vitro activation of PKA by cAMP was done to
0 5 25 50 100 500 5000
0
25000
50000
75000
100000
125000
CE2
C
(R ID)
(R IID)
c AMP(nM)
En
zy
m
e 
ac
tiv
ity
 (c
pm
)
0 5 25 50 100 500 5000
0
25000
50000
75000
100000
CD1
(R IID)
(R ID)
A
c AMP (nM)
En
zy
m
e 
ac
tiv
ity
 (c
pm
)
0 100 200 300
0
500
1000
1500
CD1
B
(R ID)
(R IID)
2 .4
8-C P T-c A MP  ( PM)
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
0 100 200 300
0
100
200
300
400
500 CE2 (R ID)
(R IID)
D
2.3
8-C PT-c AMP ( PM)
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
Figure 6 Both PKAI and PKAII are activated to phosphorylate Kemptide but not CREB at saturating conditions of cAMP. 293T cells were
co-transfected with a fixed amount (1280 ng) of either pExRIIa or pDeRIa together with pDeCa1 (300 ng) (A and B) or pDeCb2 (1400 ng) (C
and D) for 24 hours. Cell extracts were adjusted to 1 mg total protein/mL and assayed for enzyme activity (cpm,) in the presence of increasing
concentrations of cAMP (0 - 5000 nM) (A and C). Identical cell extracts were assayed for relative luciferase activity (B and D). Data points
represent relative enzyme activity and luciferase activity, +/- SD (n = 3-6).
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monitor if we had achieved comparable amounts of
PKAI and PKAII in our experiments. For monitoring in
vivo endogenous activity 8-CPT-cAMP was used
because it has cell membrane permeable properties and
is resistant to phosphodiesterase degradation [49]. The
observation that cells transfected with PKAI induced
higher levels of luciferace activity upon 8-CPT-cAMP
stimulation than cells transfected with PKAII may have
been due to relative affinities of the cAMP analogue.
We consider this unlikely since 8-CPT-cAMP is a B-site
selective cAMP analogue with higher affinity for RII
than RI [49]. Further support for 8-CPT-cAMP as a
competent activator of PKAII in vivo is found in that
the concentration of 8-CPT-cAMP used is capable of
displacing the C subunit from the RII subunit interact-
ing with the centrosome in vivo in U2OS cells [50].
Taken together we conclude that 8-CPT-cAMP is fully
capable to activate PKAII and does not selectively acti-
vate PKAI, implying that PKAII is less potent compared
with PKAI in inducing Cre-luciferase activity.
An explanation for the biological significance of the
phenomenon observed may rely on several factors.
Despite that 25% of PKA is undissociated even in the
presence of saturating concentrations of cAMP [51] it
may not account for the differences we observed since
this is observed for both PKAI and PKAII. However, it
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Figure 7 PKAII is less efficient compared to PKAI in regulating CRE activity in vivo. 293T cells were co-transfected with or without (empty
vector, M), pDeCa1 (300 ng) together with either pExRIIa (320 ng) or pDeRIa (640 ng) for 24 h (A- C). (A) R subunit-specific activity (pmol
cAMP/mg protein) was monitored in the presence of 25 μM [3H]-cAMP and showed comparable levels of RIa and RIIa. (B) Catalytic activity of
Ca1 was monitored in the absence (0) and presence of low (5 nM) and high (5000 nM) concentrations of cAMP. In the presence of 5000 nM
cAMP levels of transfected Ca1 released from RIa and RIIa were equal. (C) The stability of RIa and RIIa was monitored in the presence (+) and
absence (-) of Ca1 and the absence (0) and presence of incremental doses (1-320 μM) of 8-CPT-cAMP. R subunit stability was determined
according to immunoreactive R subunits after separation of cell extracts (25 μg total protein) on SDS-PAGE (12.5 % gels) and anti-RIa (1 : 300
dilution, upper panel) and anti-RIIa (1 : 400 dilution, lower panel). (D) 293T cells were left untreated (0) or stimulated for 1 hour with 8-CPT-
cAMP (320 μM) before harvesting. Cell extracts were adjusted to 1 mg total protein/mL and assayed for PKA-specific phosphorylation of CREB
monitored as relative luciferase activity at 560 nm. Data points represent relative luciferase activity +/- SD (n = 2-6).
Table 2 Ratios of transfected R and C subunits
PKA subunits [R]* [C] R/C ratio
Holoenzyme
PKAI 22 ± 1.5 25 ± 1.4 0.88
PKAII 23 ± 1.5 24 ± 2.9 0.96
*Concentration of R and C subunit (pmol/mg protein) were determined at
saturating concentrations of cAMP and assuming two cAMP binding sites per
R subunit and 600 pmol phosphate transferred by pure bovine C per min per
mg [65].
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has been demonstrated that cAMP-dissociated RII and
C reassociate much faster and to a much greater extent
than RI and C. In fact it has been suggested that C does
not really leave RII under physiological conditions due
to a rapid reassociation [52]. Hence, incomplete disso-
ciation of C subunit from RII even at saturating concen-
trations of cAMP could be a mechanism explaining the
phenomena observed here. Moreover, the biological sig-
nificance of differential effects of activating PKAI and
PKAII independent of C subunit identity may be multi-
ple. Recently a paper by Di and co-workers [53] demon-
strated that PKAI and PKAII define distinct intracellular
signaling compartments. They demonstrated that PKAI
and PKAII activity were regulated by distinct, spatially
restricted cAMP signals generated in response to speci-
fic G protein-coupled receptors and which were regu-
lated by unique subsets of the cAMP degrading
phosphodiesterases.
We observed that Ca1 was more active than Cb2
when expressed in non-holoenzyme form. This may sug-
gest differential Kd of Ca1 and Cb2 against RI and RII.
This suggestion was supported in that the amount of R
plasmid required for complete inhibition of Ca1 and
Cb2, respectively, was higher for RI compared to RII
regardless of C subunit identity (28 pmol RIa/mg pro-
tein and 15 pmol RIIa/mg protein for Ca1 versus
~12 pmol RIa/mg protein and ~10 pmol RIIa/mg pro-
tein for Cb2). However, we also observed that Cb2, but
not Ca1 activity was stabilized when co-transfecting
with the R subunit implying that the differences
observed is due to protein instability of the Cb2 subunit
and not lower Kd for the R subunit.
The latter is supported by the observation that R and C
dissociation by cAMP in vivo promotes degradation of C
subunits through posttranslational mechanisms which
may involve proteasome action [54]. Furthermore, it has
been shown that Ca1 and Cb1 have identical Kd values for
RI [55]. To what extent Cb2 is more sensitive to protea-
some degradation than Ca1 is not known. It should how-
ever be noted that the marked differences between the
Ca1 and Cb2 at the N-terminus has been implicated in C
subunit stability. For Ca1 it has been demonstrated that
the a-helix and Trp 30 are vital moieties for Ca1 stability.
This correlates with the location of the N-terminal at the
cleft interface where it orients the C-helix in the small
lobe and the activation loop in the large lobe so that these
subdomains are aligned in a way that allows for correct
configuration of residues at the active site [56]. Moreover,
we did not demonstrate a relative difference in potency of
Cb2 versus Ca1 in inducing Cre-luciferase activity irre-
spective of association with RIa or RIIa. The latter may
suggest that Ca1 and Cb2 behave identically in regulating
Cre-luciferase activities. Hence, we concluded that the dif-
ferential effects of PKAI and PKAII on luciferase activity
detected in the present work are associated with R subunit
but not C subunit. The latter was unexpected since it has
been speculated if the marked sequence differences at the
N-terminus will influence PKA holoenzyme features as
such as localization. The latter has previously been
demonstrated in that the N-terminus of Ca1 is implicated
in subcellular anchoring to A-kinase interacting protein 1
(AKIP1) [57]. Furthermore, at the N-terminal end the
myristoyl moiety, which binds to a hydrophobic pocket on
the surface of the large lobe when Ca1 subunit is in the
holoenzyme form [58,59], is exposed to the surroundings
upon binding to RII. This makes the holoenzyme more
hydrophobic [60]. In addition, whereas the N-terminal
Asn moiety, is involved in fine-tuning of the enzyme dis-
tribution within the cell in vivo [61], Ser10 phosphoryla-
tion is known to introduce electro statically mediated
forces which may help C to remain soluble even when
myristoylated [62-64]. Together this implies the N-term-
inal of Ca1 to contribute to regulation and tuning of sub-
cellular targeting. Despite lack of experimental evidence
the N-terminal amphiphatic a-helix in Cb2 has been pro-
posed to function as a targeting domain for Cb2 in vivo
[20]. Despite the obvious differences between Ca1 and
Cb2 we did not observe any experimental evidence on the
C subunits contributing to understand the differential
effects of PKAI and PKAII.
In perspective, the various reports referred to here
[51-53] together with our observations demonstrate dif-
ferential activities and regulation by PKAI and PKAII
which may add to understand the biological significance
of two PKA holoenzymes expressed in one cell.
Conclusions
This study is important because it points to how tissue-
dependent expression of genes encoding subunits of
PKA achieve specificity in the cAMP signaling pathway.
Our work shows that transfected PKAI holoenzymes are
more efficient than PKAII in phosphorylating CRE ele-
ments in vivo regardless of C subunit identity. Further-
more we show that Cb2 appear more stable in the
presence of R subunit than Ca1.
Methods
Cell culture
293T HEK cells were maintained in RPMI medium 1640
(Sigma) containing 10% (v/v) Fetal Bovine Serum (Sigma),
2 mM L-Glutamine (Sigma) 1% Non-essential amino
acids (Gibco), 1% Na-Pyruvat (Gibco) and 1% (v/v) Peni-
cillin/Streptomycin (Sigma). The cells were subcultured
three times weekly. Twenty hours before transfection
293T cells were grown in 6 well plates from a population
of 0.7 × 106 cells per well containing 1.5 mL RPMI
medium without Penicillin/Streptomycin. Plates were kept
at 37°C in a humidified atmosphere under 5% CO2.
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Generation and expression of PKA vectors
pEF-DEST 51™(Invitrogen) expression vectors encoding
human regulatory and catalytic subunits RIa, Ca1 and
Cb2 were created using Gateway LR Clonase Reaction®
(Invitrogen) and transformed into Library® efficiency
DH5a™Competent cells (Invitrogen). Plasmid pBlue-
script containing RIIa encoding fragment was digested
with Eag I (New England Biolabs), ligated using T4
Ligase (Promega) in plasmid pExchange 6A (Promega)
previously digested with Not I (Promega), and trans-
formed into Ultramax® DH5a™Competent cells (Invi-
trogen). Plasmids expressing catalytic subunits Ca1 or
Cb2 or/and regulatory subunits RIIa or RIa herby
termed pDeCa1, pDeCb2, pDeRIa, and pExRIIa where
transfected using Lipofectamine 2000 (Invitrogen). In
order to facilitate a reporter system, plasmids expressing
Luciferase reporter gene and b-Galactosidase as a nor-
malization control was co-transfected with R subunit
and/or C subunit in constant amounts (0.7 μg Cage-
Cre-Luciferase reporter vector and 1 μg Psv-b-Galactosi-
dase vector) in all wells except wells kept as “mock”
controls. A vector without insert was used to keep the
amount of plasmid DNA transfected constant. Cells
were stimulated with 8-CPT-cAMP for 1 or 4 hours
(specified in the text) before being harvested 24 hours
post transfection.
Immunoblot analysis
Immuno blotting was performed as previously described
[15]. Membranes were incubated with mouse monoclonal
anti-RIIb (cat # 610625, BD Transduction laboratories) at
1:250 dilution, polyclonal rabbit anti-RIb (cat # SC-907,
Santa Cruz Biotechnology, Inc.), anti-RIIa (cat # 612243,
BD Transduction laboratories) at 1:400 dilution or
mouse monoclonal anti-RIa (Clone 4D7, [65]) at 1:300
dilution. Immunoreactive proteins were detected with
HRP-conjugated secondary antibodies (ICN Diagnostics)
and SuperSignal® West Pico Chemiluminiscent (Pierce).
Phosphotransferase assays
PKA-specific catalytic activity was determined as
described previously [66]. Molar amounts of C subunit
were determined assuming 600 pmol phosphate trans-
ferred per min per mg pure bovine C.
Luciferase assay
Briefly, 24 hours post transfection cells were harvested,
lysed by sonication, and samples adjusted to equal protein
concentrations (1 mg/mL). Lysates were added appropri-
ate buffer containing 270 μM Coenzyme A (Boehringer),
530 μM ATP (Boehringer), 470 μM Luciferin (SynChem),
and immediately placed in a Luminometer (TD20/20,
Turner Designs). Luminosity was measured after 2 sec-
onds delay at 560 nm for 15 seconds with 20.1% of
intensity. Samples in the high end of luminosity were used
to create a standard curve to ensure measurement in the
linear range.
R-binding assay
The level of R-subunits was determined by specific [3H]-
cAMP binding in homogenates from transfected 293T
cells as previously described [15]. Molar amounts of R
subunits were calculated assuming two cAMP binding
sites per R subunit.
Indirect Immunofluorescence (IF)
IF of 293T cells were performed as previously described
[67]. Antibodies against RI (Clone 4D7, [65]) and RII
(cat # 612243, BD Transduction laboratories) were
diluted (see figure legend). The anti-C antibodies were
rabbit polyclonal anti-Ca 1:100 (cat # sc 903, Santa
Cruz Biotechnology, Santa Cruz, CA).
Statistics
Data are presented as means ± s.e.m and were analyzed by
unpaired two-tailed t test or by one-way analysis. A value
of <0.05 was considered statistically significant. All statis-
tics were calculated by the Graphpad prism 5.02 program.
List of abbreviations
C: catalytic subunit; CREB: cAMP-responsive element binding protein; PKA:
protein kinase A; R: regulatory subunit of PKA.
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